NEW YORK – The US Food and Drug Administration on Wednesday approved capmatinib (Novartis' Tabrecta) for treatment of patients with metastatic non-small cell lung cancer.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.